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A pre-clinical test of transplantation of
autologous iPSC-derived dopamine
neurons in a cynomolgus monkey model
of Parkinson’s disease provides proof of
principle for long-term innervation and
functional benefit without a requirement
for immunosuppression.
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Autologous transplantation of patient-specific in-
duced pluripotent stem cell (iPSC)-derived neurons
is a potential clinical approach for treatment of neuro-
logical disease. Preclinical demonstration of long-
term efficacy, feasibility, and safety of iPSC-derived
dopamine neurons in non-human primate models
will be an important step in clinical development of
cell therapy. Here, we analyzed cynomolgus monkey
(CM) iPSC-derived midbrain dopamine neurons for
up to 2 years following autologous transplantation
in a Parkinson’s disease (PD) model. In one animal,
with the most successful protocol, we found that
unilateral engraftment of CM-iPSCs could provide a
gradual onset of functional motor improvement
contralateral to the side of dopamine neuron trans-
plantation, and increased motor activity, without a
need for immunosuppression. Postmortem analyses
demonstrated robust survival of midbrain-like dopa-
minergic neurons and extensive outgrowth into the
transplanted putamen. Our proof of concept findings
support further development of autologous iPSC-
derived cell transplantation for treatment of PD.
Cellular therapies offer an exciting opportunity to replace spe-
cific populations of cells in neurodegenerative diseases where
symptoms are defined by the loss of a specific cell type, such
as the degeneration of substantia nigra (SN) dopamine neurons
in Parkinson’s disease (PD). The use of induced pluripotent
stem cell (iPSC)-derived neurons as an autologous cell source
overcomes the current limitations posed by allogeneic donor
cells in PD. Fetal ventral midbrain allografts can survive and func-
tion in the human PD brain for over 18 years (C.R. Freed et al.,
2013, Soc. Neurosci., abstract; Hallett et al., 2014; Kefalopoulou
et al., 2014; Mendez et al., 2005; Politis et al., 2010); however,
such techniques will never become an easily accessible thera-
peutic option for patients due to the requirement of fetal donor
tissue from elective abortions. Allografting in the brain also cre-Cates a greater immune reaction over time compared with isoge-
neic grafting (Duan et al., 1995; Morizane et al., 2013). The gen-
eration of midbrain-like dopamine neurons from patient-specific
iPSCs and subsequent autologous transplantation is a rational
long-term strategy for cell replacement in PD. Previous reports
of autologous transplantation in a non-human primate PD model
have demonstrated the advantage of autologous versus alloge-
neic grafts and shown dopamine neuron survival in the primate
brain for up to 6 months to 1 year after transplantation (Emborg
et al., 2013; Morizane et al., 2013; Sundberg et al., 2013). How-
ever, the long-term function, survival, and safety of iPSC-derived
dopamine neurons following autologous transplantation in a
non-human primate model of PD has not yet been established.
All studies were approved by the Harvard Medical School
Institutional Animal Care and Use Committee (IACUC). To induce
parkinsonism in cynomolgus monkeys (CMs), we administered
systemic low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP), which resulted in a progressive and persistent
reduction in global motor activity and a stable bilateral parkinso-
nian syndrome, including tremor, rigidity, bradykinesia, hypoki-
nesia, posture/balance disturbances, and impairment in both
gross and fine motor skills (Table S1) (Brownell et al., 1998a;
Hantraye et al., 1992; Wu¨llner et al., 1994). All animals displayed
a significant loss of dopamine transporters (DATs) in the puta-
men as measured by 11C-(2b-carbomethoxy-3b-(4-fluoro-
phenyl) tropane) (11C-CFT) binding potential, as previously
described (Brownell et al., 1998a). In a successive series of
studies, three MPTP-lesioned CMs (MF25-04, MF66-02, and
MF27-04) received autologous transplantation of CM-iPSC-
derived neural cells into the putamen in order to assess the
function and survival of engrafted autologous iPSC-derived
dopamine neurons. CM-iPSCs from MF25-04 were differenti-
ated using the protocol of Cooper et al. (2010), and CM-iPSCs
fromMF27-04 and MF66-02 were differentiated using the proto-
col of Sundberg et al. (2013). No animals in this study received
any immunosuppression for the duration of the study.
We recorded global daytime motor activity of MPTP-lesioned
CMs that had received autologous transplantation of iPSC-
derived neural cells, using an automated activity monitor (Fig-
ure 1A). At 6 months after transplantation, daytime activity
counts in animal MF25-04 (autologous iPSC transplant) wereell Stem Cell 16, 269–274, March 5, 2015 ª2015 Elsevier Inc. 269
Figure 1. Functional Improvement of PDMotor Symptoms, Increased Dopamine Reuptake, and Reinnervation of the Transplanted Putamen
after Autologous Transplantation of CM iPSC-Derived Dopamine Neurons
(A) Differentiated CM-iPSCs were transplanted unilaterally into the putamen of three CMs with stable, bilateral parkinsonism (MF25-04, MF66-02, MF27-04). The
animals were followed for 1–2 years after transplantation. From 6months after transplantation, functional improvement was observed in MF25-04, as determined
by a sustained increase in global daytime (6 a.m. to 6 p.m.) activity. The non-transplanted control group and non-surviving transplant group represent the average
data of n = 4 and n = 3 animals, respectively, and error bars show the SEM.
(B) Fine-motor skills in MF25-04were assessed using a computerized reaching taskMAP. At 2 years after transplantation, MAP performance in the left upper limb
was significantly improved compared with pretransplantation values (p < 0.05, one-way ANOVA followed by Tukey’s multiple comparison test). No change in
performance was observed in the right upper limb. Data shown represent averages of five repeated tests (baseline), two repeated tests (1 year after trans-
plantation), and three repeated tests (2 years after transplantation). Error bars represent the SEM.
(C) Functional analysis of dopamine reuptake in MF25-04 wasmeasured by PET neuroimaging for 11C-CFT, a marker of the DAT. Increased 11C-CFT binding was
observed in the transplanted putamen at 2 years after transplantation. White arrows indicate areas of hyperintense CFT PET signal.
(D) Low-power photomicrograph of DAT immunostaining in the transplanted (right, R) and non-transplanted (left, L) putamen in MF25-04 shows reinnervation of
the transplanted side. Deposits of grafted dopamine neurons are indicated with boxes (g). IC, internal capsule; LGP, lateral globus pallidus; LV, lateral ventricle;
3V, third ventricle; cc, corpus callosum.
(E) Grafted dopamine neurons were also labeled using tyrosine hydroxylase (TH). The boxed area is shown at higher magnification in the right. Robust survival of
dopamine neurons with outgrowth integration into the host putamen was observed.increased by 146% compared with the stable parkinsonian pre-
transplantation activity in this animal. Over the subsequent
18 months of the study, motor activity in MF25-04 remained
elevated and ranged from 178% to 292% above pretransplanta-
tion activity levels. At 2 years after transplantation, activity in this270 Cell Stem Cell 16, 269–274, March 5, 2015 ª2015 Elsevier Inc.animal was 188% of stable MPTP baseline. The stable bilateral
MPTP-lesion model used in this study provides an opportunity
to assess asymmetry in movement functions following unilateral
transplantation, using movement analysis panel (MAP) testing
(Figure 1B). A progressive improvement in the use of left
(contralateral to the graft) upper limb motor function, compared
with baseline values, was observed by 12 months after trans-
plantation in MF25-04, and this reduction reached significance
at 24 months after transplantation (p < 0.05, one-way ANOVA).
Use of right upper limbmotor function inMF25-04was not signif-
icantly altered over the 24 months following the transplantation
procedure. The severity of parkinsonian signs was also rated
monthly using a parkinsonian rating scale (Table S1). We
observed a reduction in the hypokinesia subsection of the
parkinsonian rating scale in MF25-04, from a score of 2 prior to
transplantation (maximum possible score is 3) to a score of
0 at 12 months after transplantation, and this remained stable
at 0 until completion of the study (Table S1). Overall, the time
course of functional recovery observed in MF25-04 was consis-
tent with the developmental maturation, outgrowth, and connec-
tivity of analogous fetal non-human primate dopamine neurons
(Redmond et al., 2008; Tsui and Isacson, 2011). No marked
changes in global motor activity, MAP test time, or hypokinesia
were observed in animalsMF27-04 andMF66-02 at 1–2 years af-
ter autologous transplantation of differentiated CM-iPSCs (Fig-
ure 1A; Table S1), suggestive of insufficient survival of engrafted
CM-iPSC-derived midbrain dopamine neurons and reinnerva-
tion of the transplanted putamen (Grealish et al., 2010; Redmond
et al., 2008). We also analyzed motor behavior in MPTP-lesioned
CMs that received allogeneic transplantation with differentiated
primate embryonic stem (ES) cells (Cyno-1) with no immunosup-
pression, as previously described (Sa´nchez-Pernaute et al.,
2005), in which less than 50 surviving dopaminergic neurons
were detected in the grafted putamen at postmortem (termed
the ‘‘non-surviving transplant’’ group) (n = 3), and also in non-
transplanted MPTP-lesioned CMs (n = 4) (Table S1). In the
non-surviving transplant group, animals were followed for
12 months after the transplantation procedure before termina-
tion of the study; no significant changes in motor behavior
were observed in these animals during this time (Figure 1A).
Motor behavior was also not altered over a 2-year period in the
non-transplant control group of parkinsonian animals (Figure 1A),
consistent with the long-term functional stability of this bilateral
MPTP non-human primate model (Brownell et al., 1998a; Han-
traye et al., 1992; Wu¨llner et al., 1994).
Since functional improvement in parkinsonian motor symp-
toms was observed in the MF25-04 iPSC autologous transplant
case, we performed 11C-CFT-PET scanning to assess dopamine
nerve terminals in the caudate and putamen at 2 years after
transplantation of CM-iPSC-derived neural cells (Brownell
et al., 1998a; Hantraye et al., 1992; Jenkins et al., 2004). At
2 years after transplantation, amarked increase in 11C-CFT bind-
ing sites was observed in the right putamen compared with the
non-transplanted left putamen, indicative of functional dopami-
nergic neurons on the transplanted side (Figure 1C).
Given the motor improvement and positive neuroimaging
indicative of a functional graft in MF25-04, extensive postmor-
tem examination of graft survival and morphology was per-
formed at 2 years after transplantation. Macroscopic examina-
tion of the brain showed graft deposit sites within the putamen
and normal striatal cytoarchitecture, with no displacement or
compression of the host striatal parenchyma. Immunohisto-
chemical labeling of DAT showed two distinct regions in the pu-
tamen containing clusters of DAT-immunoreactive (-ir) dopa-Cmine neurons (Figure 1D). Microscopic imaging of the entire
transplanted and non-transplanted putamen showed markedly
increased DAT labeling in the transplanted putamen compared
with the non-transplant side, indicating robust reinnervation of
the transplanted putamen from the engrafted CM-iPSC-derived
dopaminergic neurons.
Stereological cell counts of TH-ir dopamine neurons showed
the presence of 13,029 surviving transplanted dopaminergic
neurons in the putamen. Engrafted TH-ir neurons (Figure 1E)
were located predominantly around the periphery of the grafts
and extended axons into the host putamen, similar to the pattern
of A9-like dopamine neurons in rodent and human fetal VM
transplant cases (Mendez et al., 2005; Vinuela et al., 2008). As
a comparison, the number of surviving TH-ir dopamine neurons
in the transplanted putamen of the CMs MF27-04 (Sundberg
et al., 2013) and MF66-02 was also determined. These cases
received autologous transplantation of iPSC-derived dopamine
neurons, but in contrast to MF25-04, did not exhibit any func-
tional improvement at 1–2 years after transplantation. A total of
8,551 and 7,938 TH-ir dopamine neurons was present in the
transplanted putamen of MF27-04 and MF66-02, respectively.
A comparison of outgrowth of TH-ir fibers into the putamen
from the grafts of MF25-04, MF27-04, and MF66-02 showed
far more extensive dopaminergic reinnervation in MF25-04 (Fig-
ures S2A–S2C), consistent with the functional recovery
observed in this animal. These data indicate that improvement
inmotor function is achievedwhen an adequate number of trans-
planted midbrain dopamine neurons survive together with
appropriate innervation of the transplanted putamen and that
when there is not sufficient survival (less than 13,000 dopamine
neurons) and poor dopamine axonal reinnervation of the puta-
men, CMs do not recover. Our data also show that in this series
of iPSC transplantations, the Cooper et al. (2010) neuron differ-
entiation protocol was the most successful. Dopamine neuron
transplantation works at an adaptive level to provide a sufficient
number of appropriate A9 dopaminergic neurons (and their syn-
apses) in the striatum to initiate movement (function). In accord
with this, we have also previously shown following fetal dopa-
mine neuronal transplantation in a rat unilateral PDmodel (Brow-
nell et al., 1998b) that behavioral recovery only occurs after a
threshold of new striatal dopaminergic synapses is reached
(75%–85% of the intact striatum). With the development of
iPSC-derived midbrain-like dopamine neurons for clinical use
in PD, it will be essential to take into consideration that survival
of a minimal required dose of transplanted midbrain-like dopa-
mine neurons (Grealish et al., 2014) and sufficient reinnervation
of the denervated putamen is necessary for improvement of
PD motor symptoms.
Colocalization of FOXA2/TH/bIII tubulin labeling confirmed
the presence of midbrain-like dopamine neurons in the graft
of MF25-04 (Figure 2A). A separate FOXA2/TH labeling was per-
formed in parallel in each of the three CM-iPSC grafts (MF25-04,
MF27-04, and MF66-02) and showed more frequent FOXA2/TH
colabeled (midbrain-like) dopamine neurons in the graft of
MF25-04 compared with the grafts in MF27-04 and MF66-02
(Figures S2D–S2F). A punctate expression of DAT along trans-
planted TH-ir cell bodies and processes confirmed the for-
mation of mature synapses in MF25-04 (Figure 2B). For an
additional measure of neuronal health, the localization ofell Stem Cell 16, 269–274, March 5, 2015 ª2015 Elsevier Inc. 271
Figure 2. Phenotypes of Engrafted CM
iPSC-Derived Neurons at 2 Years after
Autologous Transplantation
Postmortem immunohistochemical analysis was
used to further characterize the graft in MF25-04.
(A) Immunofluorescence staining confirmed that
transplanted dopamine neurons were colabeled
for FOXA2, TH, and bIII tubulin at 2 years after
transplantation.
(B) Labeling for DAT, TH, and TOM20 (a mito-
chondrial outer membrane protein) showed a
punctate expression of DAT along the fibers of
transplanted dopamine neurons and a typical
localization of mitochondria throughout the cell
soma and neurites.
(C) Immunofluorescence staining for 5-HT
demonstrated the presence and localization of
serotonergic neurons within the graft.
(D) Labeling for DARPP-32, a marker of striatal
GABAergic medium spiny neurons, shows robust
labeling in the host putamen and occasional
DARPP-32-ir fibers at the graft-host border.
(E and F) Ki-67 was used to determine whether
proliferating cells were present in the CM-iPSC-
derived neural cell graft from MF25-04. No Ki-67-
immunoreactive cells were observed in the graft
(E). As a positive control, several Ki-67-immuno-
reactive proliferating cells were observed in the
hippocampus of the same animal (F) (identified
with arrows).
(G and H) Histological analysis of microglia using
Iba1 in the host putamen (G) and graft (H) shows
typical resting microglia.mitochondria within TH-ir neurons was assessed using the
mitochondrial marker, translocase of outer mitochondrial mem-
brane 20 (TOM20) (Hallett et al., 2014). A homogenous localiza-
tion of TOM20-ir mitochondria throughout the cell soma and
processes of transplanted neurons in MF25-04 was observed
(Figure 2B), and there was no evidence of perinuclear accumu-
lation or fragmentation of mitochondria, as has previously been
reported during dopamine neuron stress or degeneration
(Sterky et al., 2011).
Immunofluorescence labeling for 5HT (Figure 2C) was per-
formed to examine serotonergic neurons contained in the CM-
iPSC-derived transplant case, MF25-04. Serotonergic neurons
were observed with a distribution and frequency similar to that272 Cell Stem Cell 16, 269–274, March 5, 2015 ª2015 Elsevier Inc.previously reported for rodent and human
fetal VM grafts (Mendez et al., 2008; Vi-
nuela et al., 2008). Labeling for striatal me-
dium spiny GABAergic neurons in the
grafted putamen using DARPP-32 (Fig-
ure 2D) revealed robust DARPP-32 label-
ing in the host putamen perikarya and
sparse DARPP-32-ir fibers at the graft-
host border suggestive of some graft-
host interaction as has been previously re-
ported in fetal VM tissue (Doucet et al.,
1989). Immunostaining with the prolifera-
tion marker, Ki-67, showed no positively
labeled cells in the graft at 24months aftertransplantation (Figures 2E and 2F). As a positive control, several
Ki-67-labeled cells were observed in the dentate gyrus of the
same animal (MF25-04). These data are in accord with our pre-
vious work using CM-iPSC-derived neural cell xenotransplanta-
tion in rats, where a low percentage of Ki-67-ir cells at 4 weeks
after transplantation were observed, but no Ki-67-ir cells were
found in mature grafts (16 weeks after transplantation) (Deleidi
et al., 2011).
Histological analysis of microglial reactivity using immunohis-
tochemistry for Iba1 revealed a local circumscribed increase
in microglial cell density within the CM-iPSC-derived grafts
(Figures 2G, 2H, S2H, and S2I). However, Iba1 labeling was
not different to that observed in the needle tracts of the
‘‘non-surviving’’ transplant group (Figure S2G), and there was no
immune reaction in the host putamen surrounding the autolo-
gous iPSC grafts. A prior report indicates that compared with
autologous transplantation, allogeneic iPSC-derived neural cells
elicit greatermicroglial activation, as well asMHCII (class II major
histocompatibility complex) microglial expression and infiltration
of leukocytes at4months after transplantation into the non-hu-
man primate brain (Morizane et al., 2013). The route of autolo-
gous transplantation, which requires no immunosuppression,
may therefore be a more successful route for cell therapy than
using cell sources that are not completely matched to the donor.
Our work demonstrates in the successful case that dopamine
synapse innervation is accompanied by the anticipated neuro-
logical improvement in parkinsonism. However, 13,000 pri-
mate midbrain dopamine neurons were needed to reach the
threshold of functional improvements. The next steps in this
work require consistent protocols to provide equivalent or
greater midbrain dopamine neuron survival, presumably by
increasing the dose of midbrain dopamine neurons, and scale
up toward potential future clinical trials.
The present findings provide the first proof of concept preclin-
ical study to demonstrate that autologous iPSC-derived
midbrain-like dopamine neurons can engraft and survive over
an extended period of time (at least 2 years), and improve motor
function, in a non-human primate model of PD. Such autologous
iPSC-derived dopamine neurons can provide remarkable and
complete reinnervation of the denervated putamen without any
immunosuppression. We observed the most extensive dopami-
nergic axonal outgrowth reported in any study to date, including
our own and others, after engraftment with iPSC-derived dopa-
mine neurons in vivo (Emborg et al., 2013; Kikuchi et al., 2011;
Sundberg et al., 2013). In addition, in the current study, we
observed no graft overgrowth, tumor formation, or inflammatory
reaction, which is consistent with our previous rodent studies us-
ing iPSC-derived neural cells (Hargus et al., 2010; Sundberg
et al., 2013; Wernig et al., 2008).
A general concern about the use of autologous transplantation
is whether underlying PD-associated genetic mutations present
in transplanted neurons would increase the vulnerability of
midbrain dopaminergic neurons to disease pathology. However,
such vulnerabilities do not preclude cell function at a fairly
optimal level for at least 50–60 years frombirth in a typical patient
with such genetic risk (which represents a minority of PD cases).
In addition, given how transplanted fetal neurons remain healthy
for many years in PD patients, despite ongoing disease pro-
cesses in the host brain (Hallett et al., 2014), we would predict
that even in cases with severe genetic risk, iPSC-derived neu-
rons are a reasonable strategy.
In summary, our study clearly shows proof of concept for
transplantation using iPSC-derived dopamine neurons in a pre-
clinical context, and it is reasonable to infer that iPSC transplan-
tation would provide clinical benefit and expected graft survival
times similar to that observed with fetal transplantation (Barker
et al., 2013; Hallett et al., 2014; Kefalopoulou et al., 2014). Our
data showing neurologically relevant functional improvements
with concomitant positive neuroimaging are essential for the
continued development and clinical translation of cell therapy
using iPSCs. Overall, there is a strong immunological, functional,
and biological rationale for using midbrain dopamine neuronsCderived from iPSCs for cell replacement in PD in the future.
Currently, it is essential to determine the optimal and safest
dopamine neuron differentiation protocol to use, to evaluate
the generation of different (non-neuronal) cell types, and to
continue to refine the clinical protocols for generation of iPSC-
derived midbrain dopamine neurons to be used for transplanta-
tion to PD patients.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
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